FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAlnylam Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALNY
Alnylam Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Alnylam Pharmaceuticals, Inc. (ALNY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALNY
ALNY
Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALNY
  1. Home
  2. Stocks
  3. Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

🇺🇸ALNY•NASDAQ

Alnylam Pharmaceuticals, Inc.

🇺🇸ALNY•NASDAQ
Market cap
$21.39B
Sentiment

Your view on ALNY

Mkt Cap
$21.39B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Alnylam Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Yvonne L. Greenstreet
Headquarters
675 West Kendall Street, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Yvonne L. Greenstreet
Headquarters
675 West Kendall Street, Cambridge, MA, US
Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).

In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH.

Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.

Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics.

It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Alnylam Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. ALNY last traded at $159.73, 7.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Alnylam Pharmaceuticals, Inc.. Starting points for Alnylam Pharmaceuticals, Inc.: P/E 7.8, EPS $20.36, beta 0.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Alnylam Pharmaceuticals, Inc.. Alnylam Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Alnylam Pharmaceuticals, Inc.. Trailing twelve-month EPS for Alnylam Pharmaceuticals, Inc. stands at $20.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$349.21

average of 19 firms, last 12 months

 

$349.21

Low $225.00

Median $345.00

High $529.00

 

Analyst Ratings

Buy23 firms, last 12 months
  • Strong Buy0
  • Buy17
  • Hold6
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.73$1.67$19.04$8.36
Low estimate$1.35$1.33$8.39$6.70
High estimate$2.17$1.89$23.36$10.27
No. of analysts1071616
Year-ago EPS$0.82$1.511$2.331—
Growth+110.6%———

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.52B$1.48B$5.44B$6.45B
Low estimate$1.47B$1.39B$5.40B$6.01B
High estimate$1.63B$1.69B$5.50B$7.79B
No. of analysts1582122
Year-ago revenue$1.10B$1.17B$3.71B—
Growth+38.9%+26.9%+46.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 18, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Investing; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Alnylam Pharmaceuticals, Inc.. Alnylam Pharmaceuticals, Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALNY17 companies · 8 funds
Compare ALNY with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ARWRArrowhead Pharmaceuticals, Inc.Biotechnology$6.2B
  • IONSIonis Pharmaceuticals, Inc.Biotechnology$4.7B
  • NTLAIntellia Therapeutics, Inc.Biotechnology$1.4B
  • SLNSilence Therapeutics plcBiotechnology$935M
  • WVEWave Life Sciences Ltd.Biotechnology$566M

More Biotechnology companies

  • REPCFRepliCel Life Sciences Inc.OTC$7,358
  • REPLReplimune Group, Inc.NASDAQ$2.0B
  • REVBRevelation Biosciences, Inc.NASDAQ$2M
  • REVBWRevelation Biosciences, Inc.NASDAQ$27,251
  • RGBPRegen BioPharma, Inc.OTC$37,866
  • RGBPPRegen BioPharma, Inc.OTC$89,893
  • RGINRegenicin, Inc.OTC$15,348
  • RGNXREGENXBIO Inc.NASDAQ$484M
  • RGRXRegeneRx Biopharmaceuticals, Inc.OTC$449
  • RIGLRigel Pharmaceuticals, Inc.NASDAQ$823M
  • RLAYRelay Therapeutics, Inc.NASDAQ$3.8B
  • RLFTFRelief Therapeutics Holding AGOTC$12M

ETFs holding Alnylam Pharmaceuticals, Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets0.10%
  • VOVanguard Mid-Cap ETF$103.4B in assets0.21%
  • VUGVanguard Growth ETF$232.9B in assets0.08%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets2.23%
  • NUMGNuveen ESG Mid-Cap Growth$295M in assets1.86%
  • BBHVanEck Biotech ETF$536M in assets1.69%
  • QQEWFirst Trust Nasdaq-100 Select Equal Weight ETF$1.6B in assets1.47%

Largest holders first, then the funds most concentrated in ALNY.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Alnylam Pharmaceuticals, Inc., and how their positions are changing. At a $21.39B market value, institutional positions materially move Alnylam Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Alnylam Pharmaceuticals, Inc. executives and directors. Shares of Alnylam Pharmaceuticals, Inc. have traded between $205.87 and $495.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Alnylam Pharmaceuticals, Inc.. Alnylam Pharmaceuticals, Inc. is a $21.39B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Alnylam Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Alnylam Pharmaceuticals, Inc.. Coverage tracks Alnylam Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Alnylam Pharmaceuticals, Inc.

ALNY Analysis
Good
Past1
Growth5
Health3
Profit5
Value1

News

Latest Market News